Diagnostic whole genome sequencing for rare diseases: Q&A with Dr Stephen Kingsmore (Part 1)

S.KingsmoreS.Kingsmore
W.GreeneW.Greene
BulletArticle
Sequencing C-Suite Perspectives Leaders In Conversation Newborn Screening Rare Diseases
共有する：
リンクをコピーする
kingsmore part 1 thumb

As President & CEO of Rady Children’s Institute for Genomic Medicine, Dr Stephen Kingsmore plays a key role in driving access to diagnostic whole genome sequencing (WGS) services for children with symptoms of genetic disease. In this Q&A with Will Greene, Healthcare Engagement Lead for Roche Diagnostics Asia Pacific, Dr Kingsmore discusses how the institute provides rapid diagnostic WGS services to approximately 90 children’s hospitals across North America. He also shares insights on the technology trends that are making these services more powerful and cost-effective, and their potential impact on the practice of laboratory medicine. 

共有する：
リンクをコピーする

同じトピックの記事

Newborn screening for SMA: Australia’s Dr Michelle Farrar on why ‘every day counts’

Genomic newborn screening and the BeginNGS project: Q&A with Dr Stephen Kingsmore (Part 2)

おすすめのトピック

SequencingRED 2020Rare Diseases
次のおすすめ記事
  • C-Suite Perspectives, Event Coverage, Healthcare Transformation, Management, RED 2024
Dr William Morice II’s visions and considerations for building a global diagnostics ecosystem
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
  • C-Suite Perspectives, Leaders In Conversation, Management
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top